Sooma Depression Therapy
Effective & Safe
A non-invasive brain stimulation therapy
Effect size of tDCS treatment is similar to antidepressants1
No serious or systemic side effects associated with tDCS2
We believe that everyone deserves high quality care.
Sooma Depression Therapy is an effective tool for treating depression.
Treatment can also be provided by primary care and family physicians.
Provide fast and effective relief of depression to your patients without fear of systemic side effects.
Sooma Depression Therapy is a non-invasive brain stimulation therapy
Sooma Depression Therapy uses non-invasive brain stimulation to modulate the function of prefrontal areas of the brain. A portable medical device delivers electrical current to the brain for 30-minutes at a time. The aim is to normalise the hypoactivity of the left dorsolateral prefrontal cortex (DLPFC). After repeating the stimulation once a day for three weeks, symptoms are relieved for the majority of patients3. Sooma Depression Therapy is not associated with serious or systemic side effects. The treatment is painless and safe to self-administer by the patient.
The electrode placement is critical for the success of tDCS treatment. Sooma Depression Therapy utilises an intuitive headcap to position electrodes on the targeted area at each stimulation. The excitation current is delivered on the left dorsolateral prefrontal cortex (L-DLPFC) in order to increase neuronal activation in the region. The inhibition current goes through the right dorsolateral prefrontal cortex (R-DLPFC) and prevents hyperactivity in the region. As a result, the imbalance in the hemispheres of the brain, which is also typical of major depressive disorder, returns to normal.
“My patient’s mood was significantly better already during the second treatment week. Treatment affected positively also on the sensations of pain and anxiety“
Easy to apply
Figure 2. Sooma Depression Therapy utilises a small portable medical device called Sooma tDCS. The system consists of a stimulator unit, two electrodes with colour-coded cables, a head cap for electrode positioning and a stimulation pad that forms the contact surface between the skin and electrodes.
The stimulation current is delivered using Sooma tDCS™, a Class IIa medical device. The stimulator unit is indicated for the treatment of depression and chronic pain. As such, users are covered by a liability insurance when applying stimulation with Sooma tDCS to these indications.
Sooma tDCS features a single control button used to start and pause the stimulation. Everything else is automated for your convenience, and to prevent accidental modification of stimulation output. The stimulator unit is portable enabling normal movement during stimulation, so the treatments can be done while reading a book, walking a dog, office work, etc.
Figure 3. Sooma Software Suite may be used to monitor the progress of the treatment during Sooma Depression Therapy. The patient records mood and well-being data, as well as completed treatments, daily using a mobile application.
A physician is able to follow the progress of the home-based patients via Sooma Software Suite. The patients use a mobile application to record mood and well-being data. The data is synchronised in the cloud, and the physician is able to access the data via an internet browser. Using the data, the physician is able to monitor the treatment progress and edit the treatment schedule, if needed. Access to Sooma Software Suite is included in Sooma Depression Therapy.
“The results have been more than satisfying in most patients. I have had an excellent experience with Sooma tDCS therapy specifically. The device is user friendly, easy to operate and reliable.”
Fast, safe and effective
Sooma Depression Therapy is very well tolerated and has no serious side effects. 84% of patients successfully complete the treatment period, even if they have to visit the clinic for each stimulation3. A safety review, based on over 40,000 stimulation sessions, concluded that tDCS technology is safe, even used in treatment of adolescent or elderly patients2. Typical mild side effects include itching under the electrodes during the stimulation and transient headache after stimulation. The FDA has concluded that tDCS treatment is without a reasonable expectation of serious adverse events2, a position also endorsed by NICE4.
Majority of the patients undergoing Sooma Depression Therapy have shown significant alleviation of the symptoms after two weeks of treatment3. The European evidence-based guideline concluded with a level B recommendation (probable efficacy)5 and the National Institute of Care Excellence has issued a guidance on the use of tDCS4.
tDCS treatment can be safely chosen as a first treatment option for depression or it can be added-on to any ongoing therapies. There are no chemical agents involved, so there’s no risk of dangerous drug interactions. It is also safe to breastfeed when undergoing the tDCS treatment. After the initial treatment period, most patients continue with some form of maintenance treatment to prevent the relapse of depression.
“I surely would recommend Sooma Depression Therapy to patients, practically I do it pretty often. It is effective, very safe and well tolerated with no serious adverse effects and it’s really easy to use”
- Moffa, et al. Efficacy and acceptability of transcranial direct current stimulation (tDCS) for major depressive disorder: An individual patient data meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry (2019) Dec 11
- Bikson M, et al. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016 Sep-Oct;9(5):641-61.
- Sooma – Treatment Outcomes (2019) Available online: https://soomamedical.com/blog/new-and-updated-outcomes-for-sooma-depression-therapy/
- National Institute of Care Excellence – Interventional guidance IPG530 (2015) Available online: https://www.nice.org.uk/guidance/ipg530
- Lefaucheur JP et al. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation(tDCS). Clin Neurophysiol. 2017 Jan;128(1):56-92.